Hanyu Pharmaceutical announced that the company cooperated with Shenzhen Tanyunzhi Peptide Pharmaceutical Technology Co., Ltd. to develop HY3003 injections for weight loss indications. The company recently received the “Notice of Acceptance” for clinical trial applications approved and issued by the State Drug Administration. The acceptance numbers are CXHL2601095, CXHL2601096, CXHL2601097, CXHL2601098, CXHL2601099, and CXHL2601100.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.